

Z Wang et al. FAP Index.

1 Development and validation of a novel circulating fibroblast activation
2 protein - based predictive model to improve fibrosis risk stratification
3 in metabolic liver disease population.

4
5 Ziqi V Wang¹, Badwi B Boumelhem¹, Torsten Pennell¹, William W Bachovchin², Jack Hung-
6 Sen Lai², Sarah E Poplawski², Pieter Van Der Veken³, Kate Brewer¹, Geraldine Ooi⁴, Jacob
7 George⁵, Mohamed Eslam⁵, Leon A Adams⁶, Hui Emma Zhang¹, Geoffrey W McCaughan^{1,7},
8 Avik Majumdar^{1,7,8*} & Mark D Gorrell^{1*}

9
10 ¹Liver Enzymes in Metabolism and Inflammation, Centenary Institute, and The Faculty of
11 Medicine and Health, The University of Sydney, NSW, Australia; ²Department of
12 Developmental, Molecular and Chemical Biology, Graduate School of Biomedical Sciences,
13 Tufts University, Boston, Massachusetts, 02111, United States; ³Laboratory of Medicinal
14 Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, 2610 Wilrijk,
15 Belgium; Department of Surgery, ⁴Monash University, Victoria, Australia; ⁵Storr Liver Centre,
16 The Westmead Institute for Medical Research, Westmead Hospital and The University of
17 Sydney, Westmead, NSW, 2145; ⁶Medical School, Faculty of Medicine and Health Sciences,
18 The University of Western Australia, Australia; ⁷AW Morrow Gastroenterology and Liver
19 Centre, Royal Prince Alfred Hospital, Camperdown, NSW, 2050; ⁸Department of
20 Gastroenterology, Austin Hospital, Melbourne, Australia.

21
22 *Equal senior and corresponding authors. mark.gorrell@sydney.edu.au;
23 avik.majumdar@austin.org.au.

24
25
26 **Abstract:**

27
28 **Objective:**

29 Metabolic fatty liver disease drives chronic liver injury leading to fibrosis. This study aimed
30 to establish a model utilising serum circulating fibroblast activation protein (cFAP) to diagnose
31 advanced fibrosis in patients with fatty liver disease.

32 **Design:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Z Wang et al. FAP Index.

33 Two retrospective cohorts recruited from tertiary hepatology clinics were studied as training
34 (n=160) and external validation cohorts (n=342), with prevalence of histologic advanced
35 fibrosis (F3-F4) of 20% and 11%, respectively. A marker of activated mesenchymal fibrogenic
36 cells, cFAP, was measured using our single-step enzyme assay. A predictive model, FAP Index,
37 containing age, type 2 diabetes, alanine transaminase and ordinal cFAP was developed using
38 logistic regression. Diagnostic accuracy of FAP Index was assessed on a single and then
39 sequential basis.

40 **Results:**

41 FAP Index AUROC was 0.875 (95% CI 0.813-0.938) in the training cohort and 0.841 (95% CI
42 0.776-0.906) in the validation cohort. Low cut-off -1.68 (Sensitivity 80.0%, negative predictive
43 value 95.5%) and high cut-off +0.953 values (Specificity 97.7%, positive predictive value
44 88.9%) excluded and diagnosed advanced fibrosis, respectively. In the validation cohort, FAP
45 Index then FIB-4 reduced indeterminate results by one-third compared to FIB-4 alone. Whereas
46 FAP Index followed by NFS (NAFLD Fibrosis Score) resulted in a reduction of indeterminate
47 results by 70% compared to NFS alone.

48 **Conclusion:**

49 FAP Index is a novel, rapid, robust, inexpensive diagnostic tool for advanced fibrosis in
50 metabolic fatty liver disease. Applying FAP Index followed by FIB-4 or NFS facilitates
51 accurate risk-stratification of patients by greatly reducing the frequency of indeterminate
52 results compared to FIB-4 or NFS alone, without compromising negative predictive value.

53

54

55 **What is already known on this topic**

56 Fatty liver disease affects one quarter of the global population. Current screening algorithms
57 to triage those at high risk of advanced fibrosis use a dual cut-off approach that results in a
58 proportion of patients that cannot be classified (indeterminate result) and hence need further
59 and more costly testing.

60 **What this study adds**

61 We have developed the FAP Index, which is a model using a simple circulating fibroblast
62 activation protein enzyme assay and routinely available clinical variables. Using FAP Index as
63 a first-line test followed by the current recommended screening tests (FIB-4 and NFS [NAFLD
64 Fibrosis Score]) can reduce indeterminate results by up to 70% compared to the current first-
65 line standard of care tests alone, without compromising diagnostic accuracy.

Z Wang et al. FAP Index.

66 **How this study might affect research, practice or policy**

67 With recently approved pharmacotherapy for fatty liver disease, improved tools for triaging
68 people with metabolic fatty liver disease has increasing urgency. Use of FAP Index could have
69 a dramatic effect on screening for advanced fibrosis by reducing fruitless referrals to tertiary
70 care and/or further testing. Furthermore, our single-step enzymatic cFAP assay can be adapted
71 to point of care or reflex testing settings, allowing for low-cost and high throughput FAP Index
72 screening.

73

74 **Keywords:**

75 Fibrosis, Steatosis, fibroblast activation protein, diagnosis

76

77 **Number of figures: 5**

78 **Number of tables: 4**

79 **Supplemental material.**

80

81

82 **1 | Introduction**

83

84 Fatty liver disease is becoming an increasingly common metabolic disorder and currently
85 affects one quarter of the global population^{1, 2}. The pathogenesis of fatty liver disease
86 encompasses multi-factorial causes such as abnormal lipid metabolism, glucose dysregulation,
87 gut microbiome alterations and genetic variants³. These abnormal physiological changes
88 promote chronic inflammation that can lead to hepatic fibrosis, which is the most potent driver
89 towards end-stage liver disease and hepatocellular carcinoma. Moreover, obesity, type 2
90 diabetes mellitus (T2DM) and insulin resistance drive this disease^{4, 5}. Early-stage metabolic
91 fatty liver disease and hepatic fibrosis is usually asymptomatic^{6, 7}. However, the risk of liver-
92 related morbidity and mortality increases dramatically in parallel with the progression into
93 advanced hepatic fibrosis and cirrhosis^{8, 9}. As the presence of advanced fibrosis is the major
94 determinant of liver-related complications, accurately identifying those at risk in the context of
95 increasing metabolic associated fatty liver disease prevalence has become an urgent clinical
96 need for hepatologists, diabetologists and primary care physicians.

97

98 Histological assessment with liver biopsy is becoming less frequently used due to its invasive
99 and inherent sampling bias. New 3D imaging techniques highlight the latter limitation by
100 starkly revealing the uneven localisation of fibrosis¹⁰. Elastography techniques are not widely
101 accessible in the community. Therefore, non-invasive blood tests have come to the forefront
102 for the diagnosis of advanced liver fibrosis in patients with metabolic disorders. The two most
103 commonly used models are the NAFLD fibrosis score (NFS)¹¹ and the Fibrosis index-4 (FIB-
104 4)¹². However, despite being recommended for advanced fibrosis screening, these tests require
105 further optimisation^{13, 14}. Recently, the European Association for the Study of the Liver (EASL)
106 has proposed a three-step strategy including non-invasive tests (NITs) to screen for advanced
107 fibrosis¹⁵. This algorithm has been further validated for discriminating advanced fibrosis,
108 where it displays superior accuracy to a single test algorithm⁸. Despite the limitations of these
109 NITs, the application of low-cost and simple sequential NITs appears more appropriate to
110 screening in the community setting than higher cost alternatives.

111

112 Fibroblast activation protein alpha (FAP) is a dimeric type 2 trans-membrane glycoprotein with
113 proteolytic activity that degrades fibroblast growth factor 21 (FGF21)^{16, 17}, neuropeptide Y¹⁸

Z Wang et al. FAP Index.

114 and denatured collagens^{17, 19, 20}, and activates α 2-antiplasmin¹⁹. FAP is near-absent from
115 healthy tissues but highly expressed by activated stellate cells and myofibroblasts in cirrhosis²⁰⁻
116 ²². Moreover, FAP is heavily glycosylated (~30% by mass), which may confer resistance to
117 degradation that explains the persistence of soluble FAP in circulation (cFAP)²³. We previously
118 reported our specific enzyme assay of FAP^{24, 25}, and have shown that increased cFAP activity
119 associates with advanced fibrosis (F3-F4)²⁵. Additionally, cFAP activity decreases following
120 liver transplantation²⁶. Thus, cFAP activity is a potential serum biomarker for liver fibrosis that
121 derives from the cell types that produce and regulate most of the liver extracellular matrix
122 (ECM)^{17, 19}. Moreover, FAP colocalizes with ECM proteins in liver fibrosis^{22, 27, 28}. Thus, it is
123 important to explore the utility of measuring FAP when assessing fibrosis. FAP can be
124 measured by multiple approaches including specific substrate catalytic assay, antibody capture
125 catalytic assay or ELISA^{24, 29-31}. Our robust, single-step in-house FAP assay that uses a FAP-
126 specific fluorescent substrate²⁴ strongly correlates with the commercial ELISA.^{24, 26, 29-31}
127 In this study, the primary aim was to develop a NIT-based fibrosis algorithm that incorporates
128 our specific, quantitative cFAP enzyme activity assay in patients with metabolic associated
129 fatty liver disease to identify advanced fibrosis, and then to validate the performance of this
130 algorithm upon a cohort that mimics a community population. We also examined whether the
131 two most prominent FAP-specific substrates^{24, 29} generate comparable quantitative data on FAP
132 abundance in serum samples.

133

134

135 **2 | Method**

136

137 **2.1 | Study cohorts**

138 Two retrospective study cohorts were obtained from their originating hospitals. The training
139 cohort (n=160) consisted of 65 patients who underwent liver biopsy for staging of fatty liver
140 disease and 95 patients who had liver biopsy at the time of bariatric surgery at Sir Charles
141 Gairdner Hospital, Perth, Australia and has been described in part previously³². The validation
142 cohort (n=332) was pooled from two previously described study populations; 182 patients who
143 had liver biopsy at the time of bariatric surgery at The Alfred Hospital, Melbourne, Australia³³
144 and 150 patients who underwent liver biopsy for fibrosis staging of metabolic associated fatty
145 liver disease (MAFLD) at Westmead Hospital, Sydney, Australia³⁴. These cohorts were pooled
146 in order to replicate the prevalence of advanced fibrosis in an at-risk screening population of

Z Wang et al. FAP Index.

147 MAFLD, which is estimated to be 10 to 15% in Australia^{35, 36}. All included patients met
148 MAFLD criteria³⁷ and had available stored serum (-80°C) to perform cFAP assay. ³⁷ The
149 exclusion criteria were (1) alcohol related aetiology (average of >30 grams daily for men
150 and >20 grams daily for women), (2) chronic viral hepatitis and (3) non-metabolic forms of
151 liver disease. Ethics approvals were HREC_X18-0241 in Sydney Local Health District,
152 2019/ETH02319 in Westmead Hospital, RGS 01287 in Sir Charles Gairdner Hospital, and
153 195/15 in The Alfred Hospital.

154

155 **2.2 | *Clinical, demographic and histologic data***

156 Demographic data and routine clinical laboratory values (haematology and biochemistry) were
157 obtained within four weeks of the liver biopsy and measured in standardized units used in
158 Australia. Histological fibrosis assessments were performed for all included patients by the
159 pathology service in each hospital where liver biopsy occurred, as previously described.³²⁻³⁴
160 Liver fibrosis grade was evaluated according to the Kleiner pathology scoring system.³⁸ The
161 outcome variable was advanced liver fibrosis, defined as fibrosis staging >2 (F3-F4). Data were
162 de-identified.

163

164 **2.3 | *The cFAP assay***

165 The cFAP assay was performed as previously described²⁴. Briefly, 5 µL of a 1:5 dilution of
166 either human or mouse serum was pipetted into replicate wells of a 96-well plate and topped
167 up to 70 µL with tris-acetate (10 mM)-EDTA (1 mM) (pH 7.4) (TE buffer). Serial dilutions of
168 7-amino-4-methylcoumarin (0-600 pmol) were pipetted in replicate wells to a final volume of
169 100 µL per well. The plate was read on a BMG PolarStar plate reader (BMG Labtech,
170 Ortenberg, Germany) set up to read at excitation 355 nm & emission 450 nm every 2.5 mins
171 for 1 hr at 37°C.

172

173 **2.4 | *Statistical analysis***

174

175 Data are presented as median with interquartile range (IQR) due to non-parametric distribution
176 and means with standard deviation otherwise. Statistical tests were performed with exclusion
177 of missing data for variables of interest. Mann-Whitney U, one-way ANOVA where
178 appropriate. Linear correlations were assessed with Pearson's correlation coefficient.

Z Wang et al. FAP Index.

179 Univariable logistic regression was performed when the dependent variable was binary vs a
180 continuous independent variable.³⁹ Chi-square test was performed when both dependent and
181 independent variables were non-linear. The distribution of cFAP activity as a continuous
182 variable revealed extreme outliers in the training cohort (figure S1). Therefore, cFAP activity
183 was binned into 3 groups (ordinals): 0=low, 1=middle and 2=high using cut-offs at 730 and
184 1580 pmol AMC/min/mL. The low cut-off was as established by our group previously²⁵, and
185 the high cut-off was selected based on optimising specificity for advanced fibrosis. Both
186 continuous and binned cFAP activity were tested for strength of association with advanced
187 fibrosis by binary logistic regression.

188

189 To optimise diagnostic accuracy, a multivariable logistic regression model for advanced
190 fibrosis incorporating cFAP and clinical variables was developed following published
191 methods³⁹. Variables were selected for multivariable analysis if $p < 0.1$ on univariable analysis.
192 Backward elimination was then used to arrive at the final model. Interaction between predictors
193 was not accounted in this study. The Hosmer-Lemeshow test was used to assess the goodness
194 of fit of the final model, termed FAP Index. Area under the receiver operating characteristic
195 curves (AUROC) were calculated for evaluating diagnostic accuracy of FAP Index in training
196 and validation cohorts. An AUROC greater 0.7 was considered good while a score greater than
197 0.9 is outstanding⁴⁰. Dual cut-off points were chosen from the ROC curve for FAP Index to
198 optimize sensitivity and specificity in classifying patients into low- and high-risk of advanced
199 fibrosis, respectively. Positive predictive value (PPV), negative predicted value (NPV)⁴¹,
200 sensitivity, specificity and accuracy⁴¹ were calculated without the indeterminate population,
201 since that population remained 'unclassified'. FAP index, was compared with FIB-4¹² and
202 NFS¹¹, both as standalone NITs and as part of sequential NIT combinations. Complete case
203 analysis was applied upon model validation in both training and validation cohorts. FIB-4 and
204 NFS scores were calculated in only 87 patients in the training cohort due to missing data
205 (designated as the training sub-cohort), however, complete data were available for the
206 validation cohort. DeLong test was used to compare AUROCs. An alpha value of 0.05 was the
207 threshold for statistical significance. Statistical analyses were performed in R studio (version
208 2023.03.0+386) and GraphPad Prism (GraphPad, v9.4.1).

209

210 **3 | Results**

211

Z Wang et al. FAP Index.

212 **3.1 | Clinical characteristics of study cohorts**

213 Characteristics of study cohorts are presented in table 1 and supplemental table 1. There were
 214 no significant differences between the training cohort and the validation cohort except for age,
 215 the prevalence of fibrosis stages and cFAP level activities. The training cohort included more
 216 advanced fibrosis patients (20.3%) than the validation cohort (11.4%) ($P = 0.01$). Of note, there
 217 was no difference in the prevalence of type 2 diabetes (T2DM), which was 36% in the training
 218 and 30% in the validation cohort ($P = 0.21$). The median body mass index (BMI) also did not
 219 differ for the training and the validation cohorts at 38.19 (12.05) and 38.6 (14.2) kg/m^2
 220 respectively ($P = 0.89$). HOMA-IR is significantly greater in the validation cohort (2.49 (3.18))
 221 compared to the training cohort (0.4 (0.76)) ($P < 0.0001$). The cFAP activity was greater in the
 222 validation cohort (1290 (555.9) pmol AMC/min/L) than the training cohort (995.74 (579.3)
 223 pmol AMC/min/L) ($P < 0.0001$). However, there were no significant differences observed for
 224 liver enzymes. Circulating FAP was found to associate with HOMA-IR, insulin and all three
 225 liver transaminases in both cohorts ($P < 0.05$; supplemental table 2), but cFAP did not associate
 226 with T2DM.

227

228 **Table 1.** Baseline characteristics of training and validation cohort. Statistically significant
 229 differences were obtained by Mann-Whitney U test (P -value).

	Training cohort ($n=160$)	Validation cohort ($n=332$)	P -value
Age (years)	52 (18.25)	49 (19)	0.02
Gender (Male)	58 (36%)	97 (29.2%)	0.14
Diabetes (1)	57 (36%)	98 (29.6%)	0.21
BMI (kg/m^2)	38.19 (12.05)	38.6 (14.2)	0.89
ALT (U/L)	40 (42.25)	44 (45)	0.28
AST (U/L)	32.5 (20)	33 (26.3)	0.87
GGT (U/L)	40 (60.25)	42 (70.3)	0.87
Platelets (PLT; $\times 10^9/\text{L}$)	225 (94)	239 (88.3)	0.11
ALP (U/L)	81 (35.5)	Nd	Nd
Insulin (mU/L)	11 (15)	10 (11)	0.42
HOMA_IR	0.4 (0.76)	2.49 (3.18)	<0.0001
Fibrosis staging			0.02
F0	81 (51.3%)	180 (54.2%)	
F1	35 (22.2%)	84 (25.3%)	
F2	10 (6.3%)	30 (9%)	
F3	17 (10.8%)	29 (8.7%)	
F4	15 (9.5%)	9 (2.7%)	
Advanced fibrosis	32 (20.3%)	38 (11.4%)	0.01
cFAP activity (pmol AMC/min/L)	995.74 (579.3)	1290 (555.9)	<0.0001
cFAP activity ordinal			<0.0001

Z Wang et al. FAP Index.

Level 0	38 (23.8%)	15 (4.5%)
Level 1	94 (58.8%)	228 (68.7%)
Level 2	28 (17.5%)	89 (26.8%)

230 Notes: Data presented as median (IQR) for continuous variables, and prevalence (%) for categorical variables. #: The value 1 was assigned
 231 to individuals with type 2 diabetes. BMI, body mass index; ALT, Alanine transaminase; AST, Aspartate transaminase; GGT, Gamma-
 232 glutamyl transferase; ALP, alkaline phosphatase; IQR: Interquartile range.

233

234 **3.2 | FAP Enzyme assay specificity and reproducibility**

235 The specificity of our assay for FAP²⁴ has been questioned²⁹ and so was revisited and
 236 reaffirmed (supplemental material S2.1; supplemental figure 2). Robust assay reproducibility
 237 following freeze/thaw cycles and prolonged ultracold storage were established (supplemental
 238 Material S2.2; supplemental figure 3), consistent with our previous data^{24,26}.

239

240

241 **3.3 | Application of cFAP for hepatic fibrosis detection**

242 The cFAP activity was significantly associated with fibrosis (supplemental table 2). In
 243 particular, cFAP of patients with F3-F4 was significantly greater (P<0.0001) than patients
 244 without fibrosis (F0) in the training cohort (figure 1A-B), suggesting an ability to discriminate
 245 between absence of fibrosis and presence of advanced fibrosis. Significant differences in cFAP
 246 were also observed in inter-stage comparisons with moderate liver fibrosis in the validation
 247 cohort.

248

249 **3.4 | Model development for the detection of advanced fibrosis**

250 Multivariable logistic regression revealed age, T2DM, ALT and cFAP (table 2) as predictors
 251 of advanced fibrosis. We therefore derived FAP Index using the following formula:

252

$$253 \quad FAP \text{ Index} = -9.499 + 0.101 * Age + 1.533 * T2DM (0 \text{ or } 1) + 0.009 * ALT + 1.158 * \\ 254 \quad \text{ordinal_cFAP} (0, 1 \text{ or } 2)$$

255

256 **Table 2.** Associations between clinical parameters and advanced fibrosis in training cohort.^a
 257 Univariate logistic regression; ^b Chi-square test.

Parameter	Univariate association analysis			Multivariate regression model		
	Odds ratio	95% CI	P-value	Odds ratio	95% CI	P-value
Age ^a	1.11	1.05-1.16	<0.001	1.11	1.05-1.17	<0.0001

Z Wang et al. FAP Index.

Gender (Male) ^b	1.45	0.66-3.19	0.36			
Diabetes (yes/no) ^b	6.92	2.91-16.43	<0.001	4.58	1.68-12.48	<0.001
BMI ^a	0.96	0.91-1.01	0.16			
ALT ^a	1.01	1-1.01	0.01	1.01	1.00-1.02	0.02
AST ^a	1.02	1.01-1.03	0.01			
GGT ^a	1.005	1-1.01	<0.001			
PLT (x10 ⁹ /L) ^a	0.99	0.98-0.99	<0.001			
ALP ^a	1.02	1.01-1.03	<0.001			
Insulin (mU/L) ^a	1.03	1.01-1.06	0.01			
cFAP activity (pmol AMC/min/L) ^a	1.002	1.0-1.0	<0.001			
Ordinal FAP ^b			<0.001			0.002
0	-	-		-	-	
1	2.27	0.62-8.36		2.42	0.58-10.11	
2	11.67	2.9-46.96		9.24	1.86-46.01	

258 BMI, body mass index; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyl transaminase; PLT, platelets,
 259 ALP, alkaline phosphatase; cFAP, circulating fibroblast activation protein.

260

261 The Hosmer-Lemeshow test χ^2 was 3.066 (P = 0.93), indicating that FAP Index was well fitted.
 262 In the training cohort, the AUROC for FAP Index in predicting advanced fibrosis was 0.875
 263 (95% CI: 0.813 – 0.938; figure 2A). Based on the ROC, a dual cut-off strategy was applied to
 264 optimise FAP Index for ruling in and out advanced fibrosis. The low cut-off was chosen at -
 265 1.681 (sensitivity = 0.84, specificity = 0.75), and the high cut-off at 0.953 (sensitivity = 0.34,
 266 specificity = 0.99). Patients with a score lying in between these low and high cut-off scores
 267 were designated indeterminate.

268

269 The association of FAP Index with fibrosis severity (figure 1C-D) displayed better
 270 differentiation across fibrosis stages than with cFAP alone and comparable with FIB-4 (figure
 271 1E-F).

272

273 **3.5 | Comparison of FAP Index to existing NITs**

274 Only patients with complete data for FAP Index, NFS and FIB-4 were included, which was
 275 designated as the training sub-cohort (n=87). The training sub-cohort was compared with its
 276 original cohort (supplemental table 2) and was older (57 vs 52, P=0.03), had lower BMI (34 vs
 277 38, P = 0.02) and had higher insulin levels (15 vs 11, P=0.02) and cholestatic liver enzymes.
 278 Notably, there was no difference in the prevalence of advanced fibrosis. The FAP Index
 279 accuracy was numerically superior to NFS and similar to FIB-4 (AUROC 0.842, 0.779 and

Z Wang et al. FAP Index.

0.894, respectively), but without a statistically significant difference between FAP Index and FIB-4 or NFS (figure 2B). The NPVs of FAP Index, NFS and FIB-4 were 95%, 92.6% and 95.9%, respectively, with corresponding specificities of 97.7%, 80.6% and 93.8%. The sensitivities of FAP Index, NFS and FIB-4 were between 80 and 85%. Use of FAP Index and FIB-4 as standalone tests resulted in 39.1% and 32.2% of patients classified as indeterminate, respectively, whereas NFS generated 49.4% indeterminate (figure 3A-C, table 3). FAP Index, when considered, as a continuous variable, correlated with both FIB-4 and NFS ($P < 0.001$; supplemental Material S2.3; supplemental figure 4)

Table 3. Summary table for these classification analyses of all tests in the training subcohort ($n=87$), reported for NPV, PPV, proportion of indeterminate, sensitivity and specificity. *: Sensitivity and Specificity were calculated with the indeterminate results excluded.

Test performed	NPV	PPV	% Indeterminate	Sensitivity*	Specificity*
FAP Index	95.5%	88.9%	39.1%	80.0%	97.7%
FIB-4	95.7%	75.0%	32.2%	81.8%	93.8%
NFS	92.6%	64.7%	49.4%	84.6%	80.6%
FAP Index then FIB-4	92.7%	85.7%	20.7%	75.0%	96.2%
FAP Index then NFS	92.3%	88.2%	20.7%	78.9%	96.0%
FIB-4 then FAP Index	94.3%	81.3%	20.7%	81.3%	94.5%
NFS then FAP Index	91.5%	68.2%	20.7%	78.9%	86.0%

292

3.6 | FAP Index validation

The AUROC for FAP Index to predict advanced fibrosis in the validation cohort was 0.841 (figure S5). In the validation cohort, FAP Index and FIB-4 produced similar outcomes, with specificity above 98%, which were superior to NFS (specificity 64.4%). The NPVs for all three tests were above 90% (figure 4A-C, table 4). The FIB-4 sensitivity was 37.5%, while sensitivities for FAP Index and NFS were over 50%. Importantly, all tests exhibited large proportions of indeterminate: 32.6% for FAP Index, 24.1% FIB-4 and 47.5% for NFS. FAP Index was significantly correlated with FIB4 and NFS in the validation cohort ($P < 0.0001$; supplemental figure 4).

302

Table 4. Summary table for these classification analyses of all tests in the validation cohort, reported for NPV, PPV, proportion of indeterminate, sensitivity and specificity. * Sensitivity and Specificity were calculated with the indeterminate results excluded.

305

Z Wang et al. FAP Index.

Test performed	NPV	PPV	% Indeterminate	Sensitivity*	Specificity*
FAP Index	97.5%	66.7%	32.6%	54.5%	98.5%
FIB-4	95.7%	66.7%	24.1%	37.5%	98.7%
NFS	93.2%	15.9%	47.5%	58.8%	64.4%
FAP Index then FIB-4	96.4%	64.3%	16.8%	50.0%	98.0%
FAP Index then NFS	95.7%	29.7%	14.9%	52.4%	89.5%
FIB-4 then FAP Index	95.6%	58.3%	16.8%	38.9%	98.0%
NFS then FAP Index	96.0%	19.4%	14.9%	61.9%	78.2%

306

307 **3.7 | Sequential application of NITs**

308 Next, sequential application of each possible combination of NITs was performed, with the
309 primary aim to minimize the proportion of patients who were indeterminate without
310 compromising diagnostic accuracy (figure 5). All combinations and sequences of NITs
311 generated similar NPVs, above 90%, in both training cohort (table 3) and validation cohort
312 (table 4). In the training cohort, FAP Index applied as either the 1st line or 2nd line NIT in
313 combination with either NFS or FIB-4 reduced the proportion of indeterminate to 20.7% (figure
314 3D-G; table 3). In the validation cohort, FAP Index used in combination with NFS resulted in
315 14.9% indeterminates, whereas FAP Index with FIB-4 in any combination led to 16.8%
316 indeterminates (table 4, figure 4D-G). In both cohorts, the relative reduction in the
317 indeterminate population caused by adding the second line test reached 50%. However,
318 combinations of FAP Index with FIB-4 followed by FAP Index maintained specificity of ~95%
319 in both cohorts (98% in validation cohort) compared to NFS combinations with FAP Index
320 where specificity was as low as 78% in the validation cohort (tables 3 and 4). This is reflected
321 in figure 4, where although NFS combinations classified more patients as high risk, up to 80%
322 did not have histologic advanced fibrosis. Importantly, applying a step-wise test approach did
323 not influence the sensitivity and PPV compared with applying a single test. Sensitivity was
324 ~75% in the training cohort, and ~50% in the validation cohort. As expected in the validation
325 cohort where the prevalence of advanced fibrosis was lower, NPV increased and PPV reduced
326 compared to the training sub-cohort. Overall, the combination of FAP Index followed by FIB-
327 4 generated the optimal diagnostic metrics, sufficiently reducing indeterminate results while
328 maintaining an excellent NPV and acceptable PPV compared to single NITs.

329

330 **4 | Discussion**

331

Z Wang et al. FAP Index.

332 In this study, we demonstrated that circulating fibroblast activation protein (cFAP), a marker
333 of activated stellate cells and myofibroblasts, can be incorporated into an algorithm and applied
334 following NFS or FIB-4 to greatly diminish the number of indeterminate outcomes without
335 compromising sensitivity or specificity for advanced hepatic fibrosis. This novel NIT, which
336 we call FAP index, was examined in a training cohort and validated in a pooled cohort of
337 individuals with metabolic fatty liver disease with variable prevalence of biopsy proven
338 advanced fibrosis, type 2 diabetes, obesity and metabolic syndrome. The FAP Index utilises
339 cFAP and three routinely obtained parameters; age, T2DM status and ALT. We have
340 demonstrated the combination of FAP Index followed by FIB-4 provides a significant
341 reduction in indeterminate results without compromising diagnostic accuracy.

342

343 Of the variables included in FAP Index, ALT is a well-established biomarker for the severity
344 of liver injury; age is a known risk factor for progression for liver disease,⁴² T2DM and insulin
345 resistance are drivers of metabolic fatty liver disease progression, and insulin resistance
346 increases intrahepatic oxidative stress^{3, 5, 43, 44}. The presence of these variables suggests a
347 dysmetabolic state with liver injury resulting in continual hepatic stellate cell (HSC) activation.
348 We have shown that FAP is strongly associated with the presence of advanced fibrosis^{20-22, 25},
349 and FAP is found in and on activated HSC and myofibroblasts and contributes to collagen
350 turnover^{20, 21}. Moreover, new FAP/⁴²radionuclide-based 3D imaging methods have shown that
351 intrahepatic FAP strongly aligns with fibrosis severity¹⁰. Serum FAP drops following liver
352 transplantation²⁶, which suggests that liver is the origin of increased circulating FAP in patients
353 with advanced fibrosis.

354

355 In the training sub-cohort, FAP Index showed excellent accuracy in predicting the presence of
356 advanced fibrosis, with an AUROC of 0.875 (95% CI: 0.813-0.938), while FIB-4 and NFS
357 achieved comparable AUROCs of 0.899 (95% CI: 0.833-0.965) and 0.781 (95% CI: 0.672-
358 0.89) respectively. Our findings demonstrated that the FAP Index has a strong discriminating
359 capability among cohorts of varied patient composition and prevalence of advanced fibrosis.
360 However, the percentage classified as indeterminate was relatively large as standalone NIT,
361 which is an established issue for FIB-4 and NFS.

362

363 In contrast, sequentially using FAP Index with either FIB-4 or NFS was shown to dramatically
364 reduce the number of indeterminate results by between 30% and 70%, depending on the NIT

Z Wang et al. FAP Index.

365 combination.^{13, 45} Notably, the two-step strategy did not significantly alter the NPV, PPV nor
366 specificity when using FAP Index as either 1st line test or 2nd line test in combination with
367 either FIB-4 or NFS. Indeed, our group and others have shown that sequential screening tests
368 that employ dual cut-offs can increase diagnostic accuracy of NITs and thereby reduce the
369 number of biopsy referrals⁴⁶⁻⁴⁸. Similarly, a recent evaluation of the current EASL algorithm
370 by Patel and colleagues found that a stepwise strategy can improve diagnostic accuracy⁸.
371 However, the use of FIB-4 or NFS as first line NITs resulted in approximately 35% and up to
372 65% indeterminate results, respectively, in both the diabetes clinic and primary care cohorts
373 analysed. Furthermore, up to 84% needed further assessment (ie indeterminate or high-risk
374 classification) when using NFS or FIB-4⁸. In contrast, our two-step algorithm of FAP Index
375 followed by FIB-4 resulted in 39% in the training subcohort and only 21% in the validation
376 cohort who would need further investigation by the same criteria (ie indeterminate or high-risk
377 classification). This reduction compared to the Patel study was in the context of similar
378 advanced fibrosis prevalence in our training subcohort of 27%, however only 48 patients
379 underwent biopsy in the Patel cohorts.

380

381 Another advantage of the sequential combination of FAP Index with FIB-4 was the high
382 specificity. It is essential to make sure that false positives and, particularly in the context of
383 screening, that false negatives are minimized. Our validation cohort had a prevalence of
384 advanced fibrosis similar to the community of 11%^{35, 36} and using FAP Index followed by FIB-
385 4 resulted in 3.6% (9/249) false negatives and 35.7% (5/14) false positives. This strategy
386 provided the lowest rate of false negative diagnoses and comparable false positives to FIB-4
387 and NFS, in addition to the dramatic reduction in indeterminate results. This suggests that FAP
388 Index has potential benefit in community screening algorithms over current standard of care.

389

390 FAP Index has potential as a readily applicable first line test as it contains variables that are
391 easily obtained, and cFAP measurement requires only a standard fluorescence measurement
392 device, so its cost is likely to be comparable with AST and ALT. Similarly, the measurement
393 of ordinal cFAP in FAP Index could be readily modified into a point-of-care lateral flow test,
394 or as a reflex test during the measurement of liver biochemistry as part of clinical pathology
395 services.

396

Z Wang et al. FAP Index.

397 Community demand for screening for hepatic fibrosis is rising, particularly in diabetes clinics,
398 so inexpensive, simple liver fibrosis testing is needed. Although biopsy is considered as the
399 most accurate diagnostic tool in clinical guidelines, it has unavoidable pitfalls such as
400 accessibility, invasiveness, the need for specialised staff, variability between practitioners, and
401 economic impacts. While elastography is a useful alternative to biopsy, accuracy drops when
402 BMI exceeds 44, and it is influenced by operator-dependent variables and barriers still exist in
403 terms of accessibility and/or affordability⁴⁹. Therefore, the potential for FAP Index as an
404 accurate blood test and point-of-care test in routine screening could alleviate total health care
405 costs. More importantly, the enzyme activity of soluble FAP was found to have high stability
406 with extended ultracold storage²⁴ (supplemental figure2), which means that the cFAP assay is
407 amenable as a subsequent test after an initial FIB4 or NFS is completed. Thus, FAP Index as a
408 reflex test would not require an additional blood collection, which further increases
409 convenience and reduces health care expenditures.

410

411 Following a successful clinical trial⁵⁰, the U.S. Food and Drug Administration recently
412 approved a thyroid hormone receptor beta (THR- β) agonist⁵¹ as the first therapy for non-
413 cirrhotic steatohepatitis and advanced stages of liver fibrosis. This further motivates the need
414 for more accurate triage of patients with advanced fibrosis. NFS and FIB-4 are currently
415 regarded as standard of care for fibrosis screening, however, these NITs rely upon parameters
416 that are strongly associated with liver function, liver injury and inflammation, rather than
417 directly with fibrosis per se^{11, 12}. As a result, these tests can yield large proportions of
418 misclassifications among patients at high risk of metabolic fatty liver disease¹⁴. Liver fibrosis
419 is dependent on the intensity of tissue remodelling and myofibroblast activation. Therefore,
420 including a simple biomarker such as FAP that directly reflects the fibrotic process is
421 advantageous.

422

423 A major strength of this study was the robust training and validation cohorts. The prevalence
424 of fibrosis in the training cohort was similar to that of hepatology clinic populations, while the
425 validation cohort mimics community screening in an at-risk population, albeit with high
426 frequencies of obesity and diabetes. We have demonstrated that our FAP assay is robust and
427 activity can be measured via a robust and simple one-step enzyme assay. We used validated
428 methodology to arrive at the FAP Index and have performed comprehensive statistical analysis
429 to examine the influence of using different NITs alone or in combination. The study limitations

Z Wang et al. FAP Index.

430 were sample selection, sample size and non-centralised histologic fibrosis assessment.
431 Comparison of NITs in the training cohort were only available in a subset of patients, however,
432 the findings were replicated in the validation cohort.

433

434 **5 | Conclusion**

435 We have developed and validated FAP Index; a simple and novel non-invasive test for triaging
436 the risk of advanced fibrosis in metabolic associated fatty liver disease. FAP Index
437 demonstrated excellent diagnostic accuracy with an AUROC of 0.875 as a standalone test.
438 However, sequential use of FAP Index followed by FIB-4 yielded more favourable results with
439 a reduction of indeterminately classified patients by one third compared to FIB-4 alone in both
440 training and validation cohorts. This was achieved while maintaining an NPV of >95% and
441 having the lowest percentage of false negative diagnoses of any NIT strategy examined.
442 Moreover, FAP Index used sequentially with NFS compared to NFS alone generated even more
443 striking results. FAP Index includes a direct marker of fibrogenesis (cFAP), which is simple
444 and inexpensive to measure with potential application as a point of care or reflex test. Therefore,
445 FAP Index demonstrates several advantages over the current first-line standard of care NITs
446 for triaging risk of advanced fibrosis due to MAFLD and should be developed for clinical use.

447

Z Wang et al. FAP Index.

448 **ABBREVIATIONS**

449

450 ALP, alkaline phosphatase; ALT, Alanine transaminase; APRI, AST to Platelet Ratio Index;
451 AST to Platelet Ratio Index; AST, Aspartate transaminase; AUROC, area under the receiver
452 operating characteristics curve; BMI, body mass index; cFAP, circulating fibroblast
453 activation protein; ECM, extracellular matrix; ESAL, equivalent single axle load; FAP,
454 fibroblast activation protein; FGF-21, fibroblast growth factor 21; GGT, Gamma-glutamyl
455 transferase; HSC, hepatic stellate cell; IQR, inter-quartile range; MAFLD, metabolic
456 associated fatty liver disease; MRE, magnetic resonance elastography; NFS, NAFLD Fibrosis
457 Score; NIT, non-invasive test; NPV, negative predictive value; PLT, platelet; PPV, positive
458 predictive value; ROC, receiver operating characteristics curve; T2DM, type 2 diabetes
459 mellitus.

460

461 **FINANCIAL SUPPORT**

462

463 This project was funded under Australian National Health and Medical Research Council
464 project grant 1105238 (MDG, GWM, WWB), a Rebecca L Cooper Medical Research
465 Foundation (MDG) grant, Centenary Institute Foundation (MDG) and a Gilead Fellowship
466 (AM). JG is supported by: the Robert W. Storr Bequest to the Sydney Medical Foundation,
467 University of Sydney; a National Health and Medical Research Council of Australia
468 (NHMRC) Program Grant (APP1053206); Project, Ideas and Investigator grants
469 APP2001692, APP1107178, APP1108422 and APP1196492; and a Cancer Institute NSW
470 grant (2021/ATRG2028). LAA received research grant funding from the Hollywood Private
471 Hospital Research Foundation and the Sir Charles Gairdner Osborne Parke Health Care
472 Group.

473

474 **AUTHOR CONTRIBUTIONS**

475

476 ZVW: study concept and design, statistical analysis, analysis and interpretation of data, drafting
477 the manuscript; BBB: acquisition of data, review and manuscript editing, study supervision;
478 TP: study concept, statistical analysis; WWB, SEP, JHSL, PVDV, JG, LAA: Supply study
479 materials, critical revision of the manuscript; GO, ME: acquisition of study samples; KB:
480 statistical analysis and interpretation of data; HEZ: study concept and design, statistical

Z Wang et al. FAP Index.

481 analysis; GWM: acquisition of study samples, obtained funding; AM: study concept and design,
482 critical revision of the manuscript for important intellectual content, study supervision; MDG:
483 study concept and design, obtained funding, critical revision of the manuscript for important
484 intellectual content, study supervision.

485

486 **DATA AVAILABILITY STATEMENT**

487

488 All data can be achieved from corresponding authors of this paper upon reasonable request.

489

490 **Competing interests** All authors declared to have no conflict of interest to this project.

491

492 **Patient and public involvement** Patients and/or the public were not involved in the design,
493 or conduct, or reporting, or dissemination plans of this research.

494

495 **Patient consent** for this publication, Consent was not required from patients.

496

497 **Ethics approval.** The approvals were HREC_X18-0241 in Sydney Local Health District,
498 2019/ETH02319 in Westmead Hospital, RGS01287 in Sir Charles Gairdner Hospital, and
499 195/15 in The Alfred Hospital. All participants provided written informed consent and their
500 serum samples and information were handled in accordance with ethics approvals and
501 attendant regulations of each hospital.

502

503 **Supplemental material** This content has been supplied by the authors.

504

505 **ORCID IDs**

506 Ziqi V Wang <https://orcid.org/0009-0005-2725-4689>

507 Badwi Boumelhem <https://orcid.org/0000-0002-1158-123X>

508 William Bachovchin <https://orcid.org/0000-0002-9926-7244>

509 Geraldine Ooi <https://orcid.org/0000-0002-4540-408X>

510 Jacob George <https://orcid.org/0000-0002-8421-5476>

511 Leon Adams <https://orcid.org/0000-0002-3968-7909>


512 Peter van der Veken <https://orcid.org/0000-0003-1208-3571>

513 Hui Emma Zhang <https://orcid.org/0000-0002-4699-4237>

Z Wang et al. FAP Index.

- 514 Geoff McCaughan <https://orcid.org/0000-0002-1483-1636>
515 Avik Majumdar <https://orcid.org/0000-0003-2975-4327>
516 Mark Gorrell <https://orcid.org/0000-0002-0528-2604>
517

Z Wang et al. FAP Index.




518
519

520 **Figure 1.** Associations of cFAP activity, FAP Index and FIB-4 with fibrosis staging. The
521 cFAP activity (U/L) (A, B), FAP Index (C, D) and FIB-4 (E, F) segregated according to
522 fibrosis stage are displayed for training cohort (n=160) (A, C, E) and validation cohort (n =
523 332) (B, D, F). Dot plots with mean \pm SEM. Differences between groups were determined
524 using a one-way ANOVA with Tukey's post-hoc test. Significant differences are indicated


Z Wang et al. FAP Index.

525 *with asterisks to indicate degree of difference: * p-value<0.05, ** p-value<0.01, *** p-*
526 *value<0.001, **** p-value<0.0001.*

Z Wang et al. FAP Index.



527




528

Fibrosis score — FAP Index — FIB-4 — NFS

Z Wang et al. FAP Index.

529 **Figure 2.** (A) The receiver operating characteristics curve for the FAP Index in the training
530 cohort (AUROC = 0.875 with 95% CI: 0.757 – 0.927). (B) The AUROC for the FAP Index is
531 comparable with FIB-4 and NFS. Receiver operating characteristics curve of test scores in the
532 training cohort subset including FAP Index (AUROC = 0.842 with 95% CI: 0.757-0.927), FIB-
533 4 (AUROC = 0.894 with 95% CI: 0.825-0.963) and NFS (AUROC = 0.779 with 95% CI: 0.67-
534 0.889). Statistical significance between ROC curves was tested by DeLong test.


Z Wang et al. FAP Index.



Z Wang et al. FAP Index.

Figure 3. Classification analyses in training cohort. *Fibrosis stages classification as single test or sequential tests, as a function of subgroups defined by: A. FAP Index classification. B. FIB-4. C. NAFLD Fibrosis Score. D. FAP Index followed by FIB-4. E. FAP Index followed by NAFLD Fibrosis Score. F. Fibrosis stages as a function of subgroups defined by FIB-4 followed by FAP Index. G. NAFLD Fibrosis Score followed by FAP Index.*

Z Wang et al. FAP Index.



Z Wang et al. FAP Index.

Figure 4. *Classification analysis in the validation cohort. Fibrosis stages classification as a single test or sequential tests, as a function of subgroups defined by* **A.** *FAP Index classification. B. FIB-4. C. NAFLD Fibrosis Score. D. FAP Index followed by FIB-4. E. FAP Index followed by NAFLD Fibrosis Score. F. FIB-4 followed by FAP Index. G. NAFLD Fibrosis Score followed by FAP Index.*

Z Wang et al. FAP Index.




Figure 5. Flowchart for model validation in all cohorts, using two sequential tests to further classify the indeterminate patients from the 1st line screening test.

Z Wang et al. FAP Index.

References

1. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. *BMC Med.* 2017;15(1):45. Epub 2017/03/01.
2. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol.* 2021;18(4):223-38. Epub 2020/12/23.
3. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism.* 2016;65(8):1038-48. Epub 2016/01/30.
4. Fujii H, Kawada N, Japan Study Group Of Nafld J-N. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. *Int J Mol Sci.* 2020;21(11). Epub 2020/06/04.
5. Tanase DM, Gosav EM, Costea CF, et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). *J Diabetes Res.* 2020;2020:3920196. Epub 2020/08/25.
6. Ahmed M. Non-alcoholic fatty liver disease in 2015. *World J Hepatol.* 2015;7(11):1450-9. Epub 2015/06/19.
7. Kleiner DE, Makhlof HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. *Clin Liver Dis.* 2016;20(2):293-312. Epub 2016/04/12.
8. Canivet CM, Costentin C, Irvine KM, et al. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD. *Hepatology.* 2023;77(3):920-30. Epub 2022/07/14.
9. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. *Hepatology.* 2017;65(5):1557-65. Epub 2017/01/29.
10. Li H, Dai R, Huang Y, et al. [18F]AIF-ND-bisFAPi PET imaging of fibroblast activation protein as a biomarker to monitor the progression of liver fibrosis. *Hepatology Communications.* 2024;8(4):e0407.
11. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology.* 2007;45(4):846-54. Epub 2007/03/30.
12. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology.* 2006;43(6):1317-25. Epub 2006/05/27.
13. Ismaiel A, Leucuta DC, Popa SL, et al. Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis. *Panminerva Med.* 2021;63(4):508-18. Epub 2020/11/10.
14. Graupera I, Thiele M, Serra-Burriel M, et al. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. *Clin Gastroenterol Hepatol.* 2022;20(11):2567-76 e6. Epub 2022/01/01.
15. Panel EAftSotLCPG. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. *J Hepatology.* 2021;75(3):659-89. Epub 2021/06/25.
16. Coppage AL, Heard KR, DiMare MT, et al. Human FGF-21 Is a Substrate of Fibroblast Activation Protein. *PLoS One.* 2016;11(3):e0151269. Epub 2016/03/11.

Z Wang et al. FAP Index.

17. Zhang HE, Hamson EJ, Koczorowska MM, et al. Identification of Novel Natural Substrates of Fibroblast Activation Protein- α by Differential Degradomics and Proteomics. *Mol Cell Proteomics*. 2019;18(1):65-85. Epub 2018/09/28.
18. Wong PF, Gall MG, Bachovchin WW, et al. Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma. *Peptides*. 2016;75:80-95. Epub 2015/12/02.
19. Christiansen VJ, Jackson KW, Lee KN, et al. Effect of fibroblast activation protein and α 2-antiplasmin cleaving enzyme on collagen types I, III, and IV. *Arch Biochem Biophys*. 2007;457(2):177-86. Epub 2006/12/19.
20. Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. *Hepatology*. 1999;29(6):1768-78. Epub 1999/05/29.
21. Levy MT, McCaughan GW, Marinos G, et al. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. *Liver Internat*. 2002;22(2):93-101. Epub 2002/05/25.
22. Wang XM, Yu DM, McCaughan GW, et al. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. *Hepatology*. 2005;42(4):935-45. Epub 2005/09/22.
23. Lay AJ, Zhang HE, McCaughan GW, et al. Fibroblast activation protein in liver fibrosis. *Front Biosci*. 2019;24(1):1-17. Epub 2018/11/24.
24. Keane FM, Yao TW, Seelk S, et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. *FEBS Open Bio*. 2013;4:43-54. Epub 2013/12/29.
25. Williams KH, Viera de Ribeiro AJ, Prakoso E, et al. Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. *Diabetes Res Clin Pract*. 2015;108(3):466-72. Epub 2015/04/04.
26. Uitte de Willige S, Keane FM, Bowen DG, et al. Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease. *PLoS One*. 2017;12(6):e0178987. Epub 2017/06/06.
27. Gorrell MD, Wang XM, Levy MT, et al. Intrahepatic expression of collagen and fibroblast activation protein (FAP) in hepatitis C virus infection. *Adv Exp Med Biol*. 2003;524:235-43. Epub 2003/04/05.
28. Cox G, Kable E, Jones A, et al. 3-dimensional imaging of collagen using second harmonic generation. *J Struct Biol*. 2003;141(1):53-62. Epub 2003/02/11.
29. De Decker A, Vliegen G, Van Rompaey D, et al. Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP). *ACS Med Chem Lett*. 2019;10(8):1173-9. Epub 2019/08/16.
30. Song P, Pan Q, Sun Z, et al. Fibroblast activation protein α : Comprehensive detection methods for drug target and tumor marker. *Chemico-Biological Interactions*. 2022;354:109830.
31. Bainbridge TW, Dunshee DR, Kljavin NM, et al. Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP). *Sci Rep*. 2017;7(1):12524. Epub 2017/10/04.

Z Wang et al. FAP Index.

32. Adams LA, Wang Z, Liddle C, et al. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. *Liver international : official journal of the International Association for the Study of the Liver*. 2020;40(6):1356-65. Epub 2020/04/04.
33. Ooi GJ, Earnest A, Kemp WW, et al. Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. *Int J Obes (Lond)*. 2018;42(11):1900-11. Epub 2018/02/22.
34. Daniels SJ, Leeming DJ, Eslam M, et al. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. *Hepatology*. 2019;69(3):1075-86. Epub 2018/07/18.
35. Adams LA, Roberts SK, Strasser SI, et al. Nonalcoholic fatty liver disease burden: Australia, 2019–2030. *Journal of Gastroenterology and Hepatology*. 2020;35(9):1628-35.
36. Roberts SK, Majeed A, Glenister K, et al. Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study. *Medical Journal of Australia*. 2021;215(2):77-82.
37. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol*. 2020;73(1):202-9. Epub 2020/04/12.
38. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*. 2005;41(6):1313-21. Epub 2005/05/26.
39. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. *Clin Chem*. 2005;51(10):1867-73. Epub 2005/08/02.
40. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. *J Thorac Oncol*. 2010;5(9):1315-6. Epub 2010/08/26.
41. Parikh R, Mathai A, Parikh S, et al. Understanding and using sensitivity, specificity and predictive values. *Indian J Ophthalmol*. 2008;56(1):45-50. Epub 2007/12/26.
42. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol*. 2018;15(1):11-20. Epub 2017/09/21.
43. Marusic M, Paic M, Knobloch M, et al. NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. *Can J Gastroenterol Hepatol*. 2021;2021:6613827. Epub 2021/03/09.
44. Thong VD, Quynh BTH. Correlation of Serum Transaminase Levels with Liver Fibrosis Assessed by Transient Elastography in Vietnamese Patients with Nonalcoholic Fatty Liver Disease. *Int J Gen Med*. 2021;14:1349-55. Epub 2021/04/24.
45. Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. *JHEP Rep*. 2020;2(2):100067. Epub 2020/03/03.
46. Crossan C, Majumdar A, Srivastava A, et al. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis. *Liver international : official journal of the International Association for the Study of the Liver*. 2019;39(11):2052-60. Epub 2019/07/25.
47. Majumdar A, Campos S, Gurusamy K, et al. Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study. *Hepatology*. 2020;71(2):627-42. Epub 2019/07/13.

Z Wang et al. FAP Index.

48. Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. *Gut*. 2022;71(5):1006-19. Epub May 2021.
49. Eilenberg M, Munda P, Stift J, et al. Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. *Hepatobiliary Surg Nutr*. 2021;10(5):610-22. Epub 2021/11/12.
50. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. *N Engl J Med*. 2024;390(6):497-509. Epub 2024/02/07.
51. Hu L, Gu Y, Liang J, et al. Discovery of Highly Potent and Selective Thyroid Hormone Receptor beta Agonists for the Treatment of Nonalcoholic Steatohepatitis. *J Med Chem*. 2023;66(5):3284-300. Epub 2023/02/18.